Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Vascular endothelial growth factor Stories

2014-02-24 08:27:50

TARRYTOWN, N.Y., Feb. 24, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA(®) (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review of an sBLA is ten months from...

2014-02-11 08:33:10

CAMBRIDGE, Mass., Feb. 11, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in an open label single-arm Phase 2 clinical trial of its lead candidate, CRLX101, in combination with Avastin (bevacizumab) in patients with relapsed ovarian cancer. The Phase 2 combination therapy trial of this investigational treatment is being conducted at Massachusetts General Hospital (MGH) and...

2014-02-10 08:26:04

TARRYTOWN, N.Y., Feb. 10, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that in the Phase 3 VISTA-DME trial of EYLEA(®) (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100, compared to...

2014-02-06 08:29:32

American Academy of Ophthalmology advises that early detection and today's treatments for common eye disease among seniors can help stop vision loss SAN FRANCISCO, Feb. 6, 2014 /PRNewswire/ -- While age-related macular degeneration (AMD) is the leading cause of new cases of blindness in Americans age 65 and older[1], seniors who develop AMD should not consider blindness in advanced age to be inevitable, according to the American Academy of Ophthalmology. During AMD Awareness Month, the...

2014-01-22 08:28:34

Patent Provides Coverage for Lpath's Anti-S1P Antibody in the Treatment of a Wide Variety of Ocular Disorders, Including Wet AMD SAN DIEGO, Jan. 22, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark Office that the company has been issued another key patent supporting its iSONEP(TM) program. The newly issued U.S. patent, No. 8,614,103, is entitled,...

2014-01-21 10:21:17

Cancer cells have something that every prisoner longs for—a master key that allows them to escape. A study in The Journal of Cell Biology describes how a protein that promotes tumor growth also enables cancer cells to use this key and metastasize. Unless it can enter a blood or lymphatic vessel, a cancer cell is imprisoned in the tissue where it arises. The growth factor VEGF is the tumor cell's master key. It loosens connections between endothelial cells that form the lining of blood...

2014-01-13 16:26:26

GENEVA, Jan. 13, 2014 /PRNewswire/ -- Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs announced today that Opthea Pty Ltd has entered into a commercial license agreement with Selexis covering the use of the CHO-M Cell Line and related technologies for the production of OPT-302 (formerly VGX-300), an Fc fusion protein for the treatment of wet Age-Related...

2014-01-13 08:26:50

To Expand Clinical Trial for Advanced Ovarian Clear Cell Carcinoma ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of diseases, announced today that it has moved to expand its Phase 2 clinical trial for its drug candidate ENMD-2076 in advanced ovarian clear cell carcinoma (OCCC) with the submission of a new drug global clinical trial application with China's Food and Drug...

2014-01-08 08:27:45

Frost & Sullivan: Ripe for innovative, non-invasive treatments, the market will almost double by 2017 MOUNTAIN VIEW, Calif., Jan. 8, 2014 /PRNewswire/ -- The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market in the U.S. Vascular endothelial growth factor (VEGF) inhibitors dominate the market as they are a safe and effective option to treat age-related macular degeneration (AMD), diabetic macular edema...

2013-12-19 23:24:16

The authors of a new study on blood biomarkers and mesothelioma say a panel approach, including several different proteins and glycoproteins, could save lives. Raleigh, NC (PRWEB) December 19, 2013 Surviving Mesothelioma is reporting on newly-published research showing that, in the diagnosis of mesothelioma, more biomarkers are better than one. Writing in a recent issue of Anticancer Research, the scientific team suggests that a glycoprotein called chitinase-3-like-1 (YKL-40) may be an...